Haemonetics Corporation (HAE)

NYSE - NYSE Delayed Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

70.98+1.53 (+2.20%)

At close: 4:00PM EDT

70.98 0.00 (0.00%)
After hours: 04:20PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	69.45
Open	69.45
Bid	69.51 x 1000
Ask	70.84 x 4000
Day's Range	68.81 - 71.45
52 Week Range	49.26 - 142.11
Volume	389,963
Avg. Volume	485,392

Market Cap	3.622B
Beta (5Y Monthly)	0.31
PE Ratio (TTM)	56.65
EPS (TTM)	1.25
Earnings Date	Nov 09, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	79.25

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-21% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for HAE

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Haemonetics Corporation
HAE: Raising target price to $77.00HAEMONETICS CORP/MASS has an Investment Rating of BUY; a target price of $77.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
Rating
Fair Value
Economic Moat
7 days agoArgus Research

All

News

Press Releases

Research Reports

Insider Monkey
Is Haemonetics Corporation (HAE) A Good Stock To Buy?
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock […]
Simply Wall St.
Despite shrinking by US$229m in the past week, Haemonetics (NYSE:HAE) shareholders are still up 98% over 5 years
If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see...
PR Newswire
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2022 Results: November 9, 2021
Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2022 financial results at 6:00 am EST on Tuesday, November 9, 2021. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am EST on November 9, 2021.